New data show that high quality cleansing improves lesion detection during colonoscopy compared to adequate cleansing

21 April 2018

CORPORATE MEDIA RELEASE

NEW DATA SHOW THAT HIGH QUALITY CLEANSING IMPROVES LESION DETECTION DURING COLONOSCOPY COMPARED TO ADEQUATE CLEANSING[i]

 

AMSTERDAM. The Netherlands, Saturday 21 April 2018. 11:00 AM BST/12:00 CET. Norgine B.V. today announced new data showing that there is a strong correlation between higher cleansing scores and increased  polyp detection rate (PDR) and adenoma detection rate (ADR).

 

The adenoma detection rate (ADR) is one of the primary quality measures of colonoscopy and an indicator of the likelihood of subsequent patient colorectal cancer. 

 

The data were presented at the European Society for Gastrointestinal Endoscopy (ESGE) 2018, oral presentation, OP251, 21 April 2018, 11:36 to 11:48 am.

 

This post hoc analysis determined the relationship between BBPS* scores and adenoma and polyp detection rates in patients who had identical scores in each of the three colon segments, using pooled data from three similarly designed Phase 3, multicentre, randomised trials: NOCT, MORA and DAYB.

 

Overall colon lesion detection rates

High-Quality

(N=166)

Adequate

(N=950)

Low-Quality

(N=54)

Odds ratio High-Quality : Adequate

(95% CI)

[P-value]

Odds ratio Adequate :

Low-Quality

(95% CI)

[P-value]

PDR, n (%)

91 (54.8)

396 (41.7)

22 (40.7)

1.60

(1.14-2.24) [0.0067]

 

 

0.90

(0.50-1.60) [0.7104]

 

 

ADR, n (%)

71 (42.8)

247 (26.0)

15 (27.8)

1.97

(1.39-2.80) [0.0001]

 

0.75

(0.39-1.43) [0.3829]

 

 

LR Analysis of Association between Uniform BBPS Score Group and PDR, P-value

 

0.0239

LR Analysis of Association between Uniform BBPS Score Group and ADR, P-value

 

0.0006

Table 1. PDR and ADR by uniform BBPS score

 

 

Similar results were shown with the use of the Harefield Cleansing Scale** – Higher Harefield Cleansing Scale Scores are associated with improved lesion detection: post hoc analysis of three randomised and central reader-assessed phase 3 clinical trials, oral presentation, OP249, 21 April 2018, 11:12-11:24 am.[ii]

 

Dr Cesare Hassan, Gastroenterology and Endoscopic Unit, Nuovo Regina Margherita Hospital, Roma RM, Italy said: “For the first time, the use of two independent, validated, cleansing scales demonstrate that higher segmental cleansing quality is associated with higher lesion detection rates. As a result, patients should use a high quality bowel cleanser to facilitate early detection and removal of abnormalities in order to prevent colorectal cancer.”

 

Colonoscopy is a vital screening procedure to detect and remove adenomas and polyps that could otherwise lead to colorectal cancer.

 

Colorectal cancer is the second most common cause of cancer-related mortality in Europe, with over 447,000 new diagnoses every year.[iii] Colorectal cancer is largely preventable, with early detection being associated with a 90% cure rate.[iv]

 

*Boston Bowel Preparation Scale (BBPS) is a 10-point scale assessing bowel preparation after all cleansing manoeuvres are completed by the endoscopist.[v]

**Harefield Cleansing Scale is a robust, reliable, and consistent tool that has the potential to improve the effective standardization of bowel preparation assessment in both clinical and research practice.[vi]

Notes to Editors:

About MORA, NOCT AND DAYB PHASE III TRIALS

  • MORA study. A European study that compared PLENVU®to MOVIPREP® using a 2-day evening / morning split-dosing regimen and a 1-day morning only split-dosing regimen in adults. The study met both of its primary endpoints.  When administered using either dosing regimen, PLENVU® was as effective as MOVIPREP® in achieving overall bowel cleansing success, and superior to MOVIPREP® in achieving ‘high quality’ cleansing of the right colon using the Harefield Cleansing Scale (HCS).[vii]
  • NOCT study. A US study that compared PLENVU® to a trisulfate bowel cleansing solution using a 2-day evening / morning split-dosing regimen in adults. Both primary endpoints were met. PLENVU® was as effective as a trisulfate solution in achieving overall bowel cleansing success and ‘high quality’ cleansing of the right colon.[viii]
  • DAYB study. A European study that compared PLENVU® to a sodium picosulfate and magnesium salt solution using a 1-Day day before split-dosing regimen in adults. The study met both primary endpoints. PLENVU® was as effective as sodium picosulfate and magnesium salt solution at achieving overall bowel cleansing success and ‘high quality’ cleansing of the right colon.[ix]

 

 About Norgine

 

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

 

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

 

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

Media Contact:

Isabelle Jouin, T: +44 (0)1895 826237

Follow us @norgine

GL/PLV/0418/0059

 

References:

[i] Hassan C. et al. High-quality cleansing improves lesion detection during colonoscopy compared to adequate cleansing: post hoc analysis of 1170 central-reader assessed patients in three randomised phase 3 trials. Oral Presentation. ESGE 2018

[ii] Manning J. et al. Higher Harefield cleansing scale scores are associated with improved lesion detection: post hoc analysis of three randomised and central reader-assessed phase 3 clinical trials. Oral presentation. ESGE 2018

[iii] Epidemiology of colorectal cancer in Europe. Source: GLOBOCAN 2012

[iv] American Cancer Society. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/detection.html. Accessed 10 April 2018

[v]Edwin J. Lai et al. The Boston Bowel Preparation Scale: A valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009 Mar; 69(3 Pt 2): 620–625

[vi] Halphen M.. Validation of the Harefield Cleansing Scale: a tool for the evaluation of bowel cleansing quality in both research and clinical practice. Gastrointest Endosc. 2013 Jul;78(1):121-31. doi: 10.1016/j.gie.2013.02.009. Epub 2013 Mar 24

 

[vii] Bisschops R, et al. P0179. Efficacy and safety of the novel 1L PEG and ascorbate bowel preparation NER1006 versus standard 2L PEG with ascorbate in overnight or morning split-dosing administration: results from the phase 3 study MORA. UEG Journal 2016; 4(5S): A218 – A219.

[viii] DeMicco MP, Clayton LB, Pilot J et al.  Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate. Gastrointest Endosc 2017; 87(3):677-687

[ix] Schreiber, et al. P1266. Efficacy and safety of the novel 1L PEG and ascorbate bowel preparation NER1006 versus sodium picosulfate + magnesium citrate in day before split dosing administration: results from the phase 3 Study DAYB.  UEG Journal 2016; 4(5S): A589-A590

Norgine Danmark
Cookiepolitik

Sidste opdatering: 1. august 2023

 

Hvad er cookies?

Cookies er små datafiler, som hjemmesider downloader til en brugers computer, telefon eller tablet. De fleste webbrowsere accepterer automatisk cookies. De hjælper f.eks. hjemmesideudbydere med at genkende en bruger, der tidligere har besøgt en hjemmeside. Yderligere oplysninger om de cookies, der bruges på dette websted, og deres formål er beskrevet nedenfor.

 

  • Hjælpe dig med at navigere på hjemmesiden på den nemmest mulige måde
  • Hjælpe med tilmelding til vores arrangementer, login og din mulighed for at give feedback
  • Analysere brugen af webstedet (hvor mange brugere har f.eks. besøgt en bestemt side)
  • Analyse af brugen af vores produkter, tjenester eller applikationer
  • Hjælpe med vores salgsfremmende og markedsføringsmæssige indsats (herunder adfærdsbaseret annoncering)
  • Tilbyder indhold fra tredjeparter (såsom indhold fra sociale medier)

 

Detaljerede oplysninger om hver cookie kan findes i den relevante cookie-kategori i banneret samt i afsnittet nedenfor.

 

Cookie-kategori Beskrivelse

STRENGT NØDVENDIGE COOKIES

 

De strengt nødvendige cookies hjælper med at gøre en hjemmeside brugbar ved at muliggøre grundlæggende funktioner som sidenavigation og adgang til sikre områder på hjemmesiden. Disse cookies er nødvendige for, at hjemmesiden kan fungere, og de kan ikke slås fra i vores systemer. De sættes normalt kun som svar på handlinger foretaget af dig, der svarer til en anmodning om tjenester, såsom at indstille dine privatlivsindstillinger, logge ind eller udfylde formularer. Du kan muligvis afvise disse cookies via din browser, men nødvendige dele af webstedet vil så ikke fungere. Disse cookies gemmer ikke nogen personligt identificerbare oplysninger.

 

Detaljeret liste over strengt nødvendige cookies

 

FUNKTIONELLE COOKIES

Disse cookies gør det muligt for hjemmesiden at levere forbedret funktionalitet og personalisering. De kan være sat af os eller af tredjepartsudbydere, hvis tjenester vi har tilføjet til vores sider. Hvis du ikke tillader disse cookies, fungerer nogle af eller alle disse tjenester muligvis ikke korrekt.

 

Detaljeret liste over funktionelle cookies

 

PERFORMANCE-COOKIES

Disse cookies giver os mulighed for at tælle besøg og trafikkilder, så vi kan måle og forbedre ydeevnen på vores websted. De hjælper os med at vide, hvilke sider der er mest og mindst populære, og se, hvordan besøgende bevæger sig rundt på webstedet.

 

Detaljeret liste over performance-cookies

 

MARKETING-COOKIES

Disse cookies bruges til at spore vores besøgendes browsingvaner. De kan bruges til at opbygge en profil af søge- og/eller browsinghistorik for hver besøgende. Identificerbare eller unikke data indsamles for at vise relevant/personaliseret marketingindhold til hver bruger. De oplysninger, der entydigt identificerer brugernes browsere og internetenheder, bruges til at vise målrettet annoncering og/eller dele disse data med tredjeparter til samme formål.

 

Detaljeret liste over marketingcookies

 

Afvisning af cookies

Du behøver ikke at acceptere cookies, men hvis du ikke accepterer dem, kan du opleve nedsat funktionalitet på webstedet. Du kan administrere dine præferencer vedrørende cookies og andre sporingsteknologier og tilbagekalde dit samtykke i banneret. Du kan til enhver tid trække dit samtykke tilbage. Hvis du vil have flere oplysninger om sletning, deaktivering og blokering af cookies, kan du besøge hjemmesiden: https://knowcookies.com og tjekke afsnittene "Administrer cookies" og "Webmasterguide".

 

Opdatering af vores cookiepolitik

Der er mulighed for, at vi opdaterer vores cookiepolitik på denne hjemmeside i overensstemmelse med juridiske og tekniske krav, og derfor anbefaler vi, at du læser denne politik med jævne mellemrum, så du er tilstrækkeligt informeret om, hvordan og til hvad vi bruger cookies.

 

Kontakt

Hvis du har spørgsmål om denne cookiepolitik eller indsamling, behandling og videregivelse af dine personlige data og dine databeskyttelsesrettigheder, bedes du læse vores privatlivspolitik.